China Human Vaccine Industry Report, 2014-2017
  • Aug.2014
  • Hard Copy
  • USD $2,800
  • Pages:142
  • Single User License
    (PDF Unprintable)       
  • USD $2,600
  • Code: ZYM057
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,100
  • Hard Copy + Single User License
  • USD $3,000

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlier, and the market size expanded 2.8% year on year. As vaccination is suspected of causing death and some companies (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) have to shut down the production of some products after failing to pass the new GMP certification, China's human vaccine market supply and demand may witness a slight decline in 2014, but it is still expected to grow steadily in the long run.

Affected by China’s economic level, national vaccine prevention policies and people’s awareness, free EPI vaccines prevail in China with a share of approximately 80% in the total lot release volume. Also, the Chinese health authorities are trying to improve the quality of EPI vaccines. For example, Huizhou City of Guangdong province takes the lead to contain poliomyelitis inactivated vaccines into its immunization program (Sanofi Pasteur acts as a supplier in this program) for a trial in 2014. However, this program stipulates the injection of the poliomyelitis inactivated vaccine “IPV” for the first two vaccinations, while requires the oral administration of the poliomyelitis attenuated vaccine “OPV” for the third and fourth vaccinations.

Chinese human vaccine market is still dominated by Beijing Tiantan Biological, Chengdu Institute of Biology under Chinese Academy of Sciences, Shanghai Institute of Biological Products Co., Ltd. , Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises; but, their market share is falling. In 2013, the lot release volume of Chinese state-owned enterprises accounted for 69.9%, down 8.6 percentage points compared with last year; whereas, the share of private and foreign-funded enterprises jumped by 6 percentage points and 2.6 percentage points over the previous year respectively.

The improved quality of Chinese vaccines, the increased export tax rebates (from 13% in 2009 to 15%) and other favorable factors have prompted China’s human vaccine export volume and value to grow quickly. From January to June of 2014, the export volume and value amounted to 65.08 tons and USD15.45 million respectively, representing the separate increase of 115.6% and 50% over the same period of last year.

As China’s vaccine regulatory system is recognized by WHO, Chengdu Institute of Biology under Chinese Academy of Sciences, Beijing Tiantan Biological, Hualan Biological and other domestic vaccine companies are actively submitting pre-certification application to WHO in order to further expand overseas markets. In October 2013, the JE (Japanese encephalitis) vaccines of Chengdu Institute of Biology under Chinese Academy of Sciences were pre-certified by WHO at first and included in the procurement list of the United Nations. WHO inspected the influenza (split virion) vaccines of Hualan Biological on the spot in April 2014, and these vaccines are expected to be exported in 2015.

疫苗 英文_副本.jpg

The report covers the following:
20120114.gifOperating environment, status quo and sales channels of China human vaccine industry;
20120114.gifMarket supply & demand, competition patterns, import & export and development prediction of China human vaccine industry;
20120114.gifMarket supply & demand, competition patterns and market prices of 10 kinds of vaccine products including hepatitis B vaccine, influenza vaccine, rabies vaccine and pneumonia vaccine in China;
20120114.gifOperation, vaccine business and development prospects of 11 Chinese human vaccine enterprises.?

1. Overview of Vaccine Industry
1.1 Definition & classification
1.2 Industry Chain

2. China Human Vaccine Industry & Market
2.1 Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policy Environment
2.2.3 Biopharmaceutical Market in China
2.3 Status Quo
2.4 Supply & Demand
2.5 Competition Pattern
2.6 Dynamics
2.7 Sales Channel

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Market Price
3.2 Meningococcal Vaccines
3.2.1 Supply & Demand
3.2.2 Competition Pattern
3.2.3 Market Price
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Market Price
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.4.3 Market Price
3.5 Hib Vaccine
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.5.3 Market Price
3.5.4 Market Forecast
3.6 Rabies Vaccine
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.6.3 Market Price
3.6.4 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.7.3 Market Price
3.8 Pneumococcal Vaccines
3.8.1 Supply & Demand
3.8.2 Competition Pattern
3.8.3 Market Price
3.9 DTP Vaccine
3.9.1 Supply & Demand
3.9.2 Competition Pattern
3.9.3 Market Dynamics & Forecast
3.10 Poliomyelitis Vaccine
3.10.1 Supply & Demand
3.10.2 Competition Pattern

4. China’s Import and Export of Vaccines
4.1 Export
4.1.1 Export Volume and Value
4.1.2 Export Country and Region
4.2 Import
4.2.1 Import Volume and Value
4.2.2 Import Country and Region

5. Major Vaccine Manufacturers in China
5.1 China National Biotec Group
5.1.1 Beijing Tiantan Biological Products Co., Ltd
5.2 Hualan Biological Engineering Inc.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 Customers and Suppliers
5.2.6 R&D and Investment
5.2.7 Vaccine Business
5.2.8 Development and Prospects
5.3 Chongqing Zhifei Biological Products Co., Ltd
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Customers
5.3.6 R&D and Investment
5.3.7 Development and Prospects
5.4 Walvax Biotechnology Co., Ltd
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Customers and Suppliers
5.4.6 R&D and Investment
5.4.7 Development and Prospects
5.5 Sinovac Biotech Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 R&D and Investment
5.6 Liaoning Chengda Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Customers
5.6.6 Vaccine Business
5.6.7 Development and Prospects
5.7 Changchun BCHT Biotechnology Co. Ltd.
5.7.1 Profile
5.7.2 Operation
5.8 Changchun Changsheng Life Sciences Limited
5.8.1 Profile
5.8.2 Operation
5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd
5.9.1 Profile
5.9.2 Operation
5.10 Shenzhen Kangtai Biological Products Co. Ltd
5.10.1 Profile
5.10.2 Operation
5.11 Dalian Hissen Bio-Pharm Co., Ltd
5.11.1 Profile
5.11.2 Operation

Classification of Vaccines
Vaccine Industry Chain
EPI Human Vaccine Varieties in China, 2013
Global Human Vaccine Market Scale, 2008-2013
Sales Value of the Global Top 5 Human Vaccine Manufacturers, 2008-2013
Top 10 Best-selling Vaccines Worldwide, 2013
Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005- 2014
Policies in Vaccine Industry in China
Operating Revenue and Total Profit of Biological & Biochemical Product Industry in China, 2007- 2014
China’s Human Vaccine Market Scale, 2007-2013
Major Human Vaccine Varieties and Producers in China
Gross Margin of Major Human Vaccine Manufacturers in China, 2007-2013
The Release and Percentage (by Volume) of EPI and Extra EPI Vaccines in China, 2007-2013
China’s EPI Human Vaccine Market Shares by Release, 2008-2013
China’s Extra EPI Human Vaccine Market Shares by Release, 2008-2013
Vaccine Business Revenue of Key Vaccine Enterprises in China, 2011-2013
Development of Some New Vaccine in China by the end of Aug., 2014
Some Events Related to Vaccine Business of Foreign Enterprises in China, 2011-2013
Vaccine Distribution Channel in China
Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2007-2013 
Hepatitis B Vaccine (CHO Cell) Suppliers and Lot Release Volume in China, 2008-2013 
Hepatitis B Vaccine (Yeast) Suppliers and Lot Release Volume in China, 2007-2013
Market Prices of Hepatitis B Vaccine in Some Regions of China, 2014
Meningitis Morbidity and Mortality in China, 2008-2013
Meningococcal Vaccines Lot Release Volume in China by Type, 2007-2013
Suppliers and Lot Release Volume of A-Group Meningococcal Vaccines, 2007-2013 
Suppliers and Lot Release Volume of A+C Meningococcal Vaccines, 2007-2013 
Suppliers and Lot Release Volume of ACYW135 Meningococcal Vaccines in China, 2008-2013
Market Prices of Meningococcal Vaccines in Some Regions of China, 2014
Consumption Forecast of A-MCV, AC-MCV and ACYW135 in China, 2013-2017E
Hepatitis A Morbidity and Mortality in China, 2008-2013
Hepatitis A Vaccine Lot Release Volume in China, 2007-2013 
Hepatitis A Vaccine Suppliers and Lot Release Volume in China, 2007-2013
Market Price of Hepatitis A Vaccine in China, 2014
Consumption Forecast of Hepatitis A Vaccine in China, 2013-2017E
Influenza Morbidity and Mortality in China, 2008-2013
H1N1 Influenza Morbidity and Mortality in China, 2009-2012
Lot Release Volume of Influenza Vaccine in China, 2007-2013 
Suppliers and Lot Release Volume of Influenza Split Vaccine in China, 2007-2013 
Influenza Subunit Vaccine Suppliers and Lot Release Volume in China, 2007-2012 
Market Price of Influence Vaccine in China, 2014 
Hib Vaccine Lot Release Volume in China, 2007-2013 
Hib Vaccine Suppliers and Lot Release Volume in China, 2007-2013 
Market Prices of Hib Vaccine in Some Regions of China, 2014
Sales Volume of Hib Vaccine in China, 2013-2017E
Rabies Morbidity and Mortality in China, 2007-2013
Human Rabies Vaccine Lot Release Volume in China, 2007-2013
Human Rabies Vaccine Lot Release Volume in China by Type, 2007-2013 
Human Vero Cell Rabies Vaccine Suppliers and Lot Release Volume in China, 2007-2013 
Human BHK Cell Rabies Vaccine Suppliers and Lot Release Volume in China, 2007-2013 
Market Price of Human Rabies Vaccine in Some Regions of China, 2014 
Demand Forecast of Human Rabies Vaccine in China, 2012-2015
Varicella Vaccine Lot Release Volume in China, 2007-2013 
Suppliers and Lot Release Volume of Varicella Vaccine in China, 2007-2013 
Market Price of Varicella Vaccine in Some Regions of China, 2014 
Pneumococcal Vaccines Lot Release Volume in China, 2007-2013 
Suppliers of 7-valent and 23-valent Pneumococcal Vaccines and Their Lot Release Volume in China, 2007-2013
Market Prices of Pneumococcal Vaccines in Some Regions of China, 2014 
DTP Vaccine Lot Release Volume in China, 2007-2013 
DTPa Vaccine Suppliers and Lot Release Volume in China, 2007-2013
Poliomyelitis Vaccine Lot Release Volume in China, 2007-2013
Poliomyelitis Vaccine Suppliers and Lot Release Volume in China, 2007-2013 
Export Volume and Value of Human Vaccine in China, 2009- 2014
Export Average Unit Price of Human Vaccine in China, 2009- 2012
China’s Human Vaccine Export Volume and Value by Country, 2013
Import Volume and Value Human Vaccine in China, 2009- 2012
Import Average Unit Price of Human Vaccine in China, 2009- 2014
China’s Human Vaccine Import Volume and Value by Country, 2013
Major Shareholding Companies of Tiantan Biological and Their Revenue, Net Income, 2013
Revenue and Operating Income of Tiantan Biological, 2007-2014
Revenue Breakdown of Tiantan Biological by Sector, 2007-2013
Revenue Breakdown of Tiantan Biological by Region, 2007-2013
Tiantan Biological’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2013
Tiantan Biological’s Revenue from Top 5 Customers and % of Total Revenue, 2007-2013
Name List and Revenue Contribution of Tiantan Biological’s Top 5 Customers, 2013
Gross Margin of Tiantan Biological by Sector, 2007-2013
R&D Costs and % of Total Revenue of Tiantan Biological, 2009-2013
Vaccine Revenue and Gross Margin of Tiantan Biological, 2007-2013
Lot Release Volume and Proportion of Beijing Tiantan Biological by Products, 2009-2013
Revenue and Operating Income of Tiantan Biological, 2012-2017E
Revenue and Operating Income of Hualan Biological, 2007-2013
Revenue Breakdown of Hualan Biological by Sector, 2007-2013
Revenue Breakdown of Hualan Biological by Product, 2007-2013
Gross Margin of Hualan Biological by Product, 2007-2014
Hualan Biological’s Revenue from Top 5 Customers and % of Total Revenue, 2007-2013
Hualan Biological’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2012
R&D Costs and % of Total Revenue of Hualan Biological, 2007-2013
Lot Release Volume and Proportion of Hualan Biological by Products, 2011-2013
Vaccine Revenue and Gross Margin of Hualan Biological, 2008-2013
Revenue and Operating Income of Hualan Biological, 2012-2017E
Main Products of Zhifei Biological and Its Subsidiaries
Revenue and Operating Income of Zhifei Biological, 2007-2014
Revenue Breakdown of Zhifei Biological by Products, 2011-2012
Revenue Breakdown of Zhifei Biological by Products,20111-2013
Lot Release Volume and Proportion of Zhifei Biological by Products, 2011-2013
Revenue Breakdown of Zhifei Biological by Region, 2009-2013
Gross Margin of Zhifei Biological, 2009-2014
Gross Margin of Zhifei Biological’s Self- owned Products , 2008-2014
Gross Margin of Zhifei Biological’s Agent Products , 2008-2013
Zhifei Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
R&D Expenditure and Its Proportion to Revenue of Zhifei Biological, 2008-2013
Progress of the Products under Research of Zhifei Biological by the end of 2013
Revenue and Operating Income of Zhifei Biological, 2012-2017E
Industrial Layout of Walvax Biotechnology
Revenue and Operating Income of Walvax Biotechnology, 2009-2014
Revenu e Breakdown of Walvax Biotechnology by Sector, 2009-2013
Lot Release Volume and Proportion of Walvax Biotechnology by Products, 2009-2013
Revenue Breakdown of Walvax Biotechnology by Region, 2010-2013
Gross Margin of Walvax Biotechnology by Products, 2007-2013
Walvax Biotechnology’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Name List, Revenue Contribution and % to Total Revenue of Top 5 Clients of Walvax Biotechnology, 2013
Walvax Biological’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2013
R&D Costs and % of Total Revenue of Walvax Biotechnology, 2009-2013
Progress of Products under Research of Walvax Biotechnology by the end of 2013
Revenue and Operating Income of Walvax Biotechnology, 2012-2017E
Equity Structure of Sinovac Biotech Ltd
Revenue and Profit of Sinovac Biotech Ltd., 2008-2014
Vaccine Sales Volume of Sinovac Biotech Ltd by Product, 2011-2013
Revenue Breakdown of Sinovac Biotech Ltd by Products, 2008-2014
Lot Release and Proportion of Sinovac Biotech Ltd., 2008-2013
R&D Expenditure and Its Proportion to Revenue of Sinovac Biotech Ltd.,2007-2013
Revenue and Operating Income of Liaoning Chengda, 2008-2014
Revenue Breakdown of Liaoning Chengda by Sector, 2008-2013
Revenue Breakdown of Liaoning Chengda byRegion, 2008-2013
Gross Margin of Liaoning Chengda by Sector, 2008-2014
Liaoning Chengda’s Revenue from Top 5 Customers and % of Total Revenue,2008-2013
Name List, Revenue Contribution and % to Total Revenue of Top 5 Customers of Liaoning Chengda, 2013
Vaccine Revenue and Gross Margin of Liaonig Chengda, 2008-2013
Revenue and Operating Income of Liaoning Chengda, 2012-2017E
Revenue and Operating Income of Changchun BCHT, 2009-2013
Lot Release and Proportion of Changchun BCHT, 2008-2013
Lot Release and Proportion of Changchun Changsheng by product, 2008-2013
Vaccines of Zhejiang Tianyuan Bio-Pharmaceutical
Lot Rlease and Proportion of Zhejiang Tianyuan Bio-Pharmaceutical by Product, 2008-2013
Lot Release and Market Share of Kangtai Biological Hepatitis B Vaccine, 2007-2013
Lot Release and Proportion of Hissen Bio-pharm, 2009-2013
Vaccine Projects of Hissen Bio-pharm, 2013

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号